Senti Biosciences Holdings Inc（SNTI）の株式分析SNTISenti Biosciences Holdings Inc

Senti Biosciences Holdings, Inc. is a wholly owned subsidiary of Senti Holdings, Inc. Senti Biosciences, Inc. is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidate, SENTI-202, is a potentially first-in-class Logic Gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers currently being studied in an open-label, multi-center Phase I clinical trial for the treatment of relapsed/refractory hematological malignancies, including Acute Myeloid Leukemia. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Senti Biosciences Inc is not a good buy right now due to significant financial losses and declining cash reserves. The current price is $0.38, and the company reported a net income loss of $42.21 million in Q1 2026, indicating severe operational challenges. Furthermore, the RSI is at 38.22, suggesting the stock is nearing oversold territory but lacks positive momentum for recovery.